FDA
-
-
-
-
-
-
-
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Aptar nasal system delivers FDA-approved heart rhythm drug CARDAMYST
-
-
-
-
-
-
-
Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025
-
-
-
-
-
-
-
Milestone Pharmaceuticals Announces Proposed Public Offering
-
-
-
-
-
-
-
Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens
-
-
-
-
-
-
-
Milestone Pharmaceuticals (MIST) Notice of Allowance on New U.S. Patent for Etripamil
-
322,967 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

